Literature DB >> 6094674

Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children.

W P Glezen, A L Frank, L H Taber, J A Kasel.   

Abstract

In Houston the temporal occurrence of infections with parainfluenza virus type 3 has evolved from an endemic to an epidemic pattern. Continuous virological surveillance for six years demonstrated that most infections occurred the late winter or spring after influenza virus activity. At least two-thirds of children observed in the Houston Family Study were infected with this virus in each of the first two years of life, and the risk of illness was about 30/100 children per year. After two years of age, the infection and illness rates dropped to 32 and 8 per 100 child-years, respectively. Most lower-respiratory-tract disease was associated with primary infection, and the risk for infection was greater during the second year for the smaller proportion of children who escaped infection during the first year. The risk during the first year may have been modified by passively acquired maternal antibody.

Entities:  

Mesh:

Year:  1984        PMID: 6094674     DOI: 10.1093/infdis/150.6.851

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  68 in total

1.  Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.

Authors:  A A Haller; T Miller; M Mitiku; K Coelingh
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  Cyclical patterns and predictability in infection.

Authors:  N D Noah
Journal:  Epidemiol Infect       Date:  1989-04       Impact factor: 2.451

3.  Surveillance of respiratory viral infections by rapid immunofluorescence diagnosis, with emphasis on virus interference.

Authors:  G Anestad
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

4.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

5.  Inflammasome Antagonism by Human Parainfluenza Virus Type 3 C Protein.

Authors:  Niraj K Shil; Swechha M Pokharel; Amiya K Banerjee; Michael Hoffman; Santanu Bose
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

6.  Epidemiology of parainfluenza virus type 3 in England and Wales over a ten-year period.

Authors:  A J Easton; R P Eglin
Journal:  Epidemiol Infect       Date:  1989-06       Impact factor: 2.451

7.  Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.

Authors:  Roderick S Tang; Jeanne H Schickli; Mia MacPhail; Fiona Fernandes; Leenas Bicha; Joshua Spaete; Ron A M Fouchier; Albert D M E Osterhaus; Richard Spaete; Aurelia A Haller
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay.

Authors:  J Fan; K J Henrickson
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

9.  Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia.

Authors:  D D Porter; G A Prince; V G Hemming; H G Porter
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.